Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Glioblastoma Multiforme
- Determine the objective response rate to escalating doses of antineoplastons A10 and
AS2-1 in patients with glioblastoma multiforme.
- Assess tolerance to and side effects of this regimen in these patients.
OUTLINE: Patients receive gradually escalating doses of intravenous antineoplaston A10 and
antineoplaston AS2-1 6 times daily until the maximum tolerated dose is reached. Treatment
continues for at least 2 months in the absence of unacceptable toxicity or disease
progression. Patients achieving complete response (CR) continue treatment for an additional
8 months after CR.
Tumors are measured after 1 month, every 1-2 months for 2 years, every 3 months for 1 year,
every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: Not specified
Primary Purpose: Treatment
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
United States: Federal Government
|Burzynski Clinic||Houston, Texas 77055-6330|